These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23968770)

  • 1. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients.
    Fukada J; Shigematsu N; Takeuchi H; Ohashi T; Saikawa Y; Takaishi H; Hanada T; Shiraishi Y; Kitagawa Y; Fukuda K
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):487-93. PubMed ID: 23968770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.
    Ogino I; Watanabe S; Sakamaki K; Ogino Y; Kunisaki C; Kimura K
    Strahlenther Onkol; 2017 Jul; 193(7):552-560. PubMed ID: 28424841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer.
    Pao TH; Chang WL; Chiang NJ; Lin CY; Lai WW; Tseng YL; Lin FC
    Radiat Oncol; 2020 Feb; 15(1):48. PubMed ID: 32103779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy.
    Wei X; Liu HH; Tucker SL; Wang S; Mohan R; Cox JD; Komaki R; Liao Z
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):707-14. PubMed ID: 18191334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram.
    Takeuchi Y; Murakami Y; Kameoka T; Ochi M; Imano N; Takahashi I; Nishibuchi I; Kimura T; Kawahara D; Saito A; Nagata Y
    J Radiat Res; 2020 Mar; 61(2):298-306. PubMed ID: 32052040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique.
    Takata N; Kataoka M; Hamamoto Y; Tsuruoka S; Kanzaki H; Uwatsu K; Nagasaki K; Mochizuki T
    J Radiat Res; 2018 May; 59(3):291-297. PubMed ID: 29659940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
    Shaikh T; Churilla TM; Monpara P; Scott WJ; Cohen SJ; Meyer JE
    Pract Radiat Oncol; 2016; 6(6):388-394. PubMed ID: 27025161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer.
    Ogino I; Watanabe S; Iwahashi N; Kosuge M; Sakamaki K; Kunisaki C; Kimura K
    Strahlenther Onkol; 2016 Jun; 192(6):359-67. PubMed ID: 26884226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy.
    Tamari K; Isohashi F; Akino Y; Suzuki O; Seo Y; Yoshioka Y; Hayashi Y; Nishida T; Takehara T; Mori M; Doki Y; Ogawa K
    Anticancer Res; 2014 Dec; 34(12):7389-93. PubMed ID: 25503178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy.
    Hayashi K; Fujiwara Y; Nomura M; Kamata M; Kojima H; Kohzai M; Sumita K; Tanigawa N
    Br J Radiol; 2015 Feb; 88(1046):20140168. PubMed ID: 25429644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer.
    Grant JD; Shirvani SM; Tang C; Juloori A; Rebueno NC; Allen PK; Chang JY
    Pract Radiat Oncol; 2015; 5(4):e383-91. PubMed ID: 25731965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer.
    Fukada J; Shigematsu N; Ohashi T; Shiraishi Y; Takeuchi H; Kawaguchi O; Kitagawa Y
    J Radiat Res; 2012; 53(3):447-53. PubMed ID: 22739014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
    Wang SL; Liao Z; Vaporciyan AA; Tucker SL; Liu H; Wei X; Swisher S; Ajani JA; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):692-9. PubMed ID: 16242257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.
    Xue J; Han C; Jackson A; Hu C; Yao H; Wang W; Hayman J; Chen W; Jin J; Kalemkerian GP; Matuzsak M; Jolly S; Kong FS
    Radiother Oncol; 2019 Apr; 133():213-219. PubMed ID: 30416046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer.
    Isohashi F; Yoshioka Y; Mabuchi S; Konishi K; Koizumi M; Takahashi Y; Ogata T; Maruoka S; Kimura T; Ogawa K
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):728-34. PubMed ID: 22727885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Ning MS; Tang L; Gomez DR; Xu T; Luo Y; Huo J; Mouhayar E; Liao Z
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):70-79. PubMed ID: 28816165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
    Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-volume histogram parameters and clinical factors associated with pleural effusion after chemoradiotherapy in esophageal cancer patients.
    Shirai K; Tamaki Y; Kitamoto Y; Murata K; Satoh Y; Higuchi K; Nonaka T; Ishikawa H; Katoh H; Takahashi T; Nakano T
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1002-7. PubMed ID: 20542385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
    Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.